Search

Your search keyword '"Kats-Ugurlu, G"' showing total 152 results
Start Over Author "Kats-Ugurlu, G"
152 results on '"Kats-Ugurlu, G"'

3. Analysis of metastases rates during follow-up after endoscopic resection of early “high-risk” esophageal adenocarcinoma

Author

Karrenbeld, A., Ooms, A., Huysentruyt, C., ten Kate, F., Moll, F., Kats-Ugurlu, G., van Lijnschoten, I., van de Laan, J., Offerhaus, J., Biermann, K., Seldenrijk, K., Brosens, L., Meijer, S., Doukas, M., Nieuwenhuis, Esther A., van Munster, Sanne N., Meijer, Sybren L., Brosens, Lodewijk A.A., Jansen, Marnix, Weusten, Bas L.A. M., Alvarez Herrero, Lorenza, Alkhalaf, Alaa, Schenk, Ed, Schoon, Erik J., Curvers, Wouter L., Koch, Arjun D., van de Ven, Steffi E.M., Verheij, Eva P.D., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M. G., Tang, Thjon, Bergman, Jacques J.G. H.M., and Pouw, Roos E.

Published
2022
Full Text
View/download PDF

4. P119 Single-cell RNA sequencing in Inflammatory Bowel Disease in patients with Primary Sclerosing Cholangitis: a distinct form of colitis

Author

Bangma, A, primary, Pibiri, P, additional, Sun, S, additional, Bigaeva, E, additional, De Jong, S, additional, Bjørk, J, additional, Verstappen, G M P J, additional, Kats-Ugurlu, G, additional, Hermoso, M A, additional, Vich Vila, A, additional, van der Wijst, M G P, additional, Faber, K N, additional, Weersma, R K, additional, Uniken Venema, W T C, additional, and Festen, E, additional

Published
2024
Full Text
View/download PDF

6. Prophylactic Medication for the Prevention of Endoscopic Recurrence in Crohn's Disease: a Prospective Study Based on Clinical Risk Stratification.

Author

Arkenbosch, J.H.C., Beelen, E.M.J., Dijkstra, G., Romberg-Camps, M., Duijvestein, M., Hoentjen, F., Marel, S. van der, Maljaars, P.W.J., Jansen, Sita, Boer, N.K. de, West, R.L., Horjus, C.S., Stassen, L.P., Schaik, F.D. van, Ruler, O. van, Jharap, B.J.H., Visschedijk, M., Janssen, A., Erler, N.S., Doukas, M., Ooms, A.H.A.G., Kats-Ugurlu, G., Woude, C.Janneke van der, Vries, A.C.M. de, Arkenbosch, J.H.C., Beelen, E.M.J., Dijkstra, G., Romberg-Camps, M., Duijvestein, M., Hoentjen, F., Marel, S. van der, Maljaars, P.W.J., Jansen, Sita, Boer, N.K. de, West, R.L., Horjus, C.S., Stassen, L.P., Schaik, F.D. van, Ruler, O. van, Jharap, B.J.H., Visschedijk, M., Janssen, A., Erler, N.S., Doukas, M., Ooms, A.H.A.G., Kats-Ugurlu, G., Woude, C.Janneke van der, and Vries, A.C.M. de

Abstract

Item does not contain fulltext, BACKGROUND: To prevent recurrence after ileocolonic resection [ICR] in Crohn's disease [CD], postoperative prophylaxis based on risk stratification is recommended in international guidelines. This study aimed to evaluate postoperative CD recurrence after implementation of a clinical management algorithm and to determine the predictive value of clinical and histological risk factors [RFs]. METHODS: In this multicentre, prospective cohort study, CD patients [≥16 years] scheduled for ICR were included. The algorithm advised no postoperative medication for low-risk patients, and treatment with prophylaxis [immunosuppressant/biological] for high-risk patients [≥1 RF: active smoking, penetrating disease, prior ICR]. Clinical and histological RFs [active inflammation, granulomas, plexitis in resection margins] for endoscopic recurrence [Rutgeerts' score ≥i2b at 6 months] were assessed using logistic regression and ROC curves based on predicted probabilities. RESULTS: In total, 213 CD patients after ICR were included [age 34.5 years; 65% women] (93 [44%] low-risk; 120 [56%] high-risk: 45 [38%] smoking; 51 [43%] penetrating disease; 51 [43%] prior ICR). Adherence to the algorithm was 82% in low-risk [no prophylaxis] and 51% in high-risk patients [prophylaxis]. Endoscopic recurrence was higher in patients treated without prophylaxis than with prophylaxis in both low [45% vs 16%, p = 0.012] and high-risk patients [49% vs 26%, p = 0.019]. Clinical risk stratification including the prescription of prophylaxis corresponded to an area under the curve [AUC] of 0.70 (95% confidence interval [CI] 0.61-0.79). Clinical RFs combined with histological RFs increased the AUC to 0.73 [95% CI 0.64-0.81]. CONCLUSION: Adherence to this management algorithm is 65%. Prophylactic medication after ICR prevents endoscopic recurrence in low- and high-risk patients. Clinical risk stratification has an acceptable predictive value, but further refinement is needed.

Published
2023

7. Ultrasound-guided needle biopsy fluorescence spectroscopy with quantitative fluorescence endoscopy for response monitoring in patients with esophageal cancer after neoadjuvant chemoradiotherapy using bevacizumab-800CW

Author

Schmidt, I., additional, Van Der Waaij, A. M., additional, Kats-Ugurlu, G., additional, Dijkstra, F. A., additional, Haveman, J. W., additional, Etten, B. Van, additional, Robinson, D. J., additional, and Nagengast, W., additional

Published
2023
Full Text
View/download PDF

8. Fluorescently labelled vedolizumab identified macroscopic and microscopic mucosal drug distribution and target cells in patients with inflammatory bowel disease

Author

van der Waaij, A. M., additional, Gabriels, R. Y., additional, Linssen, M. D., additional, Volkmer, P., additional, Dobosz, M., additional, Robinson, D. J., additional, Hermoso, M. A., additional, Karrenbeld, A., additional, Festen, E.A. M., additional, Dijkstra, G., additional, Kats-Ugurlu, G., additional, and Nagengast, W. B., additional

Published
2023
Full Text
View/download PDF

9. Limited risk of residual cancer after endoscopic resection of early Barrett’s neoplasia with confirmed vertical R1 margin: a nationwide cohort in the Netherlands

Author

Tilburg, L. van, additional, Verheij, E.P. D., additional, Van De Ven, S.E. M., additional, Van Munster, S. N., additional, Weusten, B.L.A. M., additional, Herrero, L. Alvarez, additional, Brosens, L.A. A., additional, Raicu, G. M., additional, Nagengast, W. B., additional, Westerhof, J., additional, Kats-Ugurlu, G., additional, Schoon, E. J., additional, Curvers, W. L., additional, Van Lijnschoten, I. G., additional, Alkhalaf, A., additional, Moll, F.C. P., additional, De Jonge, P.J. F., additional, Houben, M.H.M. G., additional, Van Der Laan, J. S., additional, Tang, T. J., additional, Ooms, A.H.A. G., additional, Bergman, J.J.G.H. M., additional, Pouw, R. E., additional, Oudijk, L., additional, Doukas, M., additional, Meijer, S. L., additional, Jansen, M., additional, and Koch, A. D., additional

Published
2023
Full Text
View/download PDF

10. Prophylactic Medication for the Prevention of Endoscopic Recurrence in Crohn's Disease:a Prospective Study Based on Clinical Risk Stratification

Author

Arkenbosch, J.H.C., Beelen, E.M.J., Dijkstra, G., Romberg-Camps, M., Duijvestein, M., Hoentjen, F., Marel, S. van der, Maljaars, P.W.J., Jansen, S., Boer, N.K.H. de, West, R.L., Horjus, C.S., Stassen, L.P.S., Schaik, F.D.M. van, Ruler, O. van, Jharap, B.J.H., Visschedijk, M., Janssen, A., Erler, N.S., Doukas, M., Ooms, A.H.A.G., Kats-Ugurlu, G., Woude, C.J. van der, Vries, A.C. de, Dutch Initiative Crohns Colitis IC, Surgery, MUMC+: MA Heelkunde (9), RS: NUTRIM - R2 - Liver and digestive health, RS: SHE - R1 - Research (OvO), Gastroenterology & Hepatology, Epidemiology, Pathology, Gastroenterology and hepatology, Amsterdam Gastroenterology Endocrinology Metabolism, Groningen Institute for Organ Transplantation (GIOT), Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), and Translational Immunology Groningen (TRIGR)

Subjects
Crohn’s disease, Crohn's disease, All institutes and research themes of the Radboud University Medical Center, Gastroenterology, postoperative recurrence, Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], General Medicine, Ileocecal resection, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]
Abstract

Background To prevent recurrence after ileocolonic resection [ICR] in Crohn’s disease [CD], postoperative prophylaxis based on risk stratification is recommended in international guidelines. This study aimed to evaluate postoperative CD recurrence after implementation of a clinical management algorithm and to determine the predictive value of clinical and histological risk factors [RFs]. Methods In this multicentre, prospective cohort study, CD patients [≥16 years] scheduled for ICR were included. The algorithm advised no postoperative medication for low-risk patients, and treatment with prophylaxis [immunosuppressant/biological] for high-risk patients [≥1 RF: active smoking, penetrating disease, prior ICR]. Clinical and histological RFs [active inflammation, granulomas, plexitis in resection margins] for endoscopic recurrence [Rutgeerts’ score ≥i2b at 6 months] were assessed using logistic regression and ROC curves based on predicted probabilities. Results In total, 213 CD patients after ICR were included [age 34.5 years; 65% women] (93 [44%] low-risk; 120 [56%] high-risk: 45 [38%] smoking; 51 [43%] penetrating disease; 51 [43%] prior ICR). Adherence to the algorithm was 82% in low-risk [no prophylaxis] and 51% in high-risk patients [prophylaxis]. Endoscopic recurrence was higher in patients treated without prophylaxis than with prophylaxis in both low [45% vs 16%, p = 0.012] and high-risk patients [49% vs 26%, p = 0.019]. Clinical risk stratification including the prescription of prophylaxis corresponded to an area under the curve [AUC] of 0.70 (95% confidence interval [CI] 0.61–0.79). Clinical RFs combined with histological RFs increased the AUC to 0.73 [95% CI 0.64–0.81]. Conclusion Adherence to this management algorithm is 65%. Prophylactic medication after ICR prevents endoscopic recurrence in low- and high-risk patients. Clinical risk stratification has an acceptable predictive value, but further refinement is needed.

Published
2023
Full Text
View/download PDF

11. Analysis of metastases rates during follow-up after endoscopic resection of early “high-risk” esophageal adenocarcinoma

Author

Nieuwenhuis, Esther A., primary, van Munster, Sanne N., additional, Meijer, Sybren L., additional, Brosens, Lodewijk A.A., additional, Jansen, Marnix, additional, Weusten, Bas L.A. M., additional, Alvarez Herrero, Lorenza, additional, Alkhalaf, Alaa, additional, Schenk, Ed, additional, Schoon, Erik J., additional, Curvers, Wouter L., additional, Koch, Arjun D., additional, van de Ven, Steffi E.M., additional, Verheij, Eva P.D., additional, Nagengast, Wouter B., additional, Westerhof, Jessie, additional, Houben, Martin H.M. G., additional, Tang, Thjon, additional, Bergman, Jacques J.G. H.M., additional, Pouw, Roos E., additional, Karrenbeld, A., additional, Ooms, A., additional, Huysentruyt, C., additional, ten Kate, F., additional, Moll, F., additional, Kats-Ugurlu, G., additional, van Lijnschoten, I., additional, van de Laan, J., additional, Offerhaus, J., additional, Biermann, K., additional, Seldenrijk, K., additional, Brosens, L., additional, Meijer, S., additional, and Doukas, M., additional

Published
2022
Full Text
View/download PDF

14. P284 Prophylactic medication for the prevention of endoscopic recurrence after ileocolonic resection in Crohn’s disease: a prospective study based on clinical risk stratification

Author

Arkenbosch, J H, primary, Beelen, E M J, additional, Dijkstra, G, additional, Romberg-Camps, M, additional, Duijvestein, M, additional, Hoentjen, F, additional, van der Marel, S, additional, Maljaars, P W J, additional, Jansen, S, additional, de Boer, N K, additional, West, R, additional, Horjus, C, additional, Stassen, L P S, additional, van Schaik, F, additional, van Ruler, O, additional, Jharap, B J H, additional, Erler, N E, additional, Doukas, M, additional, Ooms, A H A G, additional, Kats-Ugurlu, G, additional, van der Woude, J, additional, and De Vries, A C, additional

Published
2022
Full Text
View/download PDF

18. The Small Intestine is Protected by the Presence of Luminal Preservation Solution During Cold Storage in a Brain-dead Rat Model

Author

Trentadue, G., Vecchio, L., Kats-Ugurlu, G., Ivanoff Marinoff, I., Vernengo, J., Haveman, J., Rumbo, M., Faber, K., Leuvenink, H., Dijkstra, G., Center for Liver, Digestive and Metabolic Diseases (CLDM), Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Groningen Institute for Organ Transplantation (GIOT), and Translational Immunology Groningen (TRIGR)

Published
2021

19. Clinically Applicable PEG-based Intraluminal Preservation of Human Small Intestines Does Not Reduce Histological Damage Compared to Standard Vascular Flush

Author

Trentadue, G., Clarysse, M., de Jong, A., van Praagh, J., Canovai, E., Kats-Ugurlu, G., Haveman, J., Pirenne, J., Leuvenink, H., Faber, K., Ceulemans, L., Dijkstra, G., Groningen Institute for Organ Transplantation (GIOT), Center for Liver, Digestive and Metabolic Diseases (CLDM), Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), and Translational Immunology Groningen (TRIGR)

Published
2021

20. Significant variation in histopathological assessment of endoscopic resections for Barrett's neoplasia suggests need for consensus reporting: propositions for improvement

Author

van der Wel, M J, primary, Klaver, E, additional, Pouw, R E, additional, Brosens, L A A, additional, Biermann, K, additional, Doukas, M, additional, Huysentruyt, C, additional, Karrenbeld, A, additional, ten Kate, F J W, additional, Kats-Ugurlu, G, additional, van der Laan, J, additional, van Lijnschoten, I, additional, Moll, F C P, additional, Offerhaus, G J A, additional, Ooms, A H A G, additional, Seldenrijk, C A, additional, Visser, M, additional, Tijssen, J G, additional, Meijer, S L, additional, and Bergman, J J G H M, additional

Published
2021
Full Text
View/download PDF

22. Significant variation in histopathological assessment of endoscopic resections for Barrett's neoplasia suggests need for consensus reporting: propositions for improvement

Author

Wel, M.J.C. van der, Klaver, E., Pouw, R.E., Brosens, L.A.A., Biermann, K., Doukas, M., Huysentruyt, C., Karrenbeld, A., Kate, F.J. ten, Kats-Ugurlu, G., Laan, J. van der, Lijnschoten, I. Van, Moll, F.C.P., Offerhaus, G.J.A., Ooms, A., Seldenrijk, C.A., Visser, M. de, Tijssen, J.G., Meijer, S.L., Bergman, J., Wel, M.J.C. van der, Klaver, E., Pouw, R.E., Brosens, L.A.A., Biermann, K., Doukas, M., Huysentruyt, C., Karrenbeld, A., Kate, F.J. ten, Kats-Ugurlu, G., Laan, J. van der, Lijnschoten, I. Van, Moll, F.C.P., Offerhaus, G.J.A., Ooms, A., Seldenrijk, C.A., Visser, M. de, Tijssen, J.G., Meijer, S.L., and Bergman, J.

Abstract

Item does not contain fulltext, Endoscopic resection (ER) is an important diagnostic step in management of patients with early Barrett's esophagus (BE) neoplasia. Based on ER specimens, an accurate histological diagnosis can be made, which guides further treatment. Based on depth of tumor invasion, differentiation grade, lymphovascular invasion, and margin status, the risk of lymph node metastases and local recurrence is judged to be low enough to justify endoscopic management, or high enough to warrant invasive surgical esophagectomy. Adequate assessment of these histological risk factors is therefore of the utmost importance. Aim of this study was to assess pathologist concordance on these histological features on ER specimens and evaluate causes of discrepancy. Of 62 challenging ER cases, one representative H&E slide and matching desmin and endothelial marker were digitalized and independently assessed by 13 dedicated GI pathologists from 8 Dutch BE expert centers, using an online assessment module. For each histological feature, concordance and discordance were calculated. Clinically relevant discordances were observed for all criteria. Grouping depth of invasion categories according to expanded endoscopic treatment criteria (T1a and T1sm1 vs. T1sm2/3), ≥1 pathologist was discrepant in 21% of cases, increasing to 45% when grouping diagnoses according to the traditional T1a versus T1b classification. For differentiation grade, lymphovascular invasion, and margin status, discordances were substantial with 27%, 42%, and 32% of cases having ≥1 discrepant pathologist, respectively. In conclusion, histological assessment of ER specimens of early BE cancer by dedicated GI pathologists shows significant discordances for all relevant histological features. We present propositions to improve definitions of diagnostic criteria.

Published
2021

23. Lymphovascular invasion quantification could improve risk prediction of lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma

Author

Ven, S.E.M. van de, Suzuki, L., Gotink, A.W., Kate, F.J. ten, Nieboer, D., Weusten, B., Brosens, L.A.A., Hillegersberg, R. van, Herrero, L. Alvarez, Seldenrijk, C.A., Alkhalaf, A., Moll, F.C.P., Curvers, W., Lijnschoten, I.G. van, Tang, T.J., Valk, H. van der, Nagengast, W.B., Kats-Ugurlu, G., Plukker, J.T., Houben, M, Laan, J.S. van der, Pouw, R.E., Bergman, J., Meijer, S.L., Henegouwen, M.I. van Berge, Wijnhoven, B.P., Jonge, P.J.F. de, Doukas, M., Bruno, M.J., Biermann, K., Koch, A.D., Ven, S.E.M. van de, Suzuki, L., Gotink, A.W., Kate, F.J. ten, Nieboer, D., Weusten, B., Brosens, L.A.A., Hillegersberg, R. van, Herrero, L. Alvarez, Seldenrijk, C.A., Alkhalaf, A., Moll, F.C.P., Curvers, W., Lijnschoten, I.G. van, Tang, T.J., Valk, H. van der, Nagengast, W.B., Kats-Ugurlu, G., Plukker, J.T., Houben, M, Laan, J.S. van der, Pouw, R.E., Bergman, J., Meijer, S.L., Henegouwen, M.I. van Berge, Wijnhoven, B.P., Jonge, P.J.F. de, Doukas, M., Bruno, M.J., Biermann, K., and Koch, A.D.

Abstract

Item does not contain fulltext, AIM: To quantify lymphovascular invasion (LVI) and to assess the prognostic value in patients with pT1b esophageal adenocarcinoma. METHODS: In this nationwide, retrospective cohort study, patients were included if they were treated with surgery or endoscopic resection for pT1b esophageal adenocarcinoma. Primary endpoint was the presence of metastases, lymph node metastases, or distant metastases, in surgical resection specimens or during follow-up. A prediction model to identify risk factors for metastases was developed and internally validated. RESULTS: 248 patients were included. LVI was distributed as follows: no LVI (n = 196; 79.0%), 1 LVI focus (n = 16; 6.5%), 2-3 LVI foci (n = 21; 8.5%) and ≥4 LVI foci (n = 15; 6.0%). Seventy-eight patients had metastases. The risk of metastases was increased for tumors with 2-3 LVI foci [subdistribution hazard ratio (SHR) 3.39, 95% confidence interval (CI) 2.10-5.47] and ≥4 LVI foci (SHR 3.81, 95% CI 2.37-6.10). The prediction model demonstrated a good discriminative ability (c-statistic 0.81). CONCLUSION: The risk of metastases is higher when more LVI foci are present. Quantification of LVI could be useful for a more precise risk estimation of metastases. This model needs to be externally validated before implementation into clinical practice.

Published
2021

24. Performance of gastrointestinal pathologists within a national digital review panel for Barrett's oesophagus in the Netherlands: results of 80 prospective biopsy reviews

Author

Klaver, E., Wel, M. van der, Duits, L., Pouw, R., Seldenrijk, K., Offerhaus, J., Visser, Mike, Kate, F. Ten, Biermann, K., Brosens, L.A.A., Doukas, M., Huysentruyt, C., Karrenbeld, A., Kats-Ugurlu, G., Laan, J. van der, Lijnschoten, I. Van, Moll, F., Ooms, A., Tijssen, J., Meijer, S., Bergman, J., Klaver, E., Wel, M. van der, Duits, L., Pouw, R., Seldenrijk, K., Offerhaus, J., Visser, Mike, Kate, F. Ten, Biermann, K., Brosens, L.A.A., Doukas, M., Huysentruyt, C., Karrenbeld, A., Kats-Ugurlu, G., Laan, J. van der, Lijnschoten, I. Van, Moll, F., Ooms, A., Tijssen, J., Meijer, S., and Bergman, J.

Abstract

Contains fulltext : 245220.pdf (Publisher’s version ) (Open Access), AIMS: The histopathological diagnosis of low-grade dysplasia (LGD) in Barrett's oesophagus (BO) is associated with poor interobserver agreement and guidelines dictate expert review. To facilitate nationwide expert review in the Netherlands, a web-based digital review panel has been set up, which currently consists of eight 'core' pathologists. The aim of this study was to evaluate if other pathologists from the Dutch BO expert centres qualify for the expert panel by assessing their performance in 80 consecutive LGD reviews submitted to the panel. METHODS: Pathologists independently assessed digital slides in two phases. Both phases consisted of 40 cases, with a group discussion after phase I. For all cases, a previous consensus diagnosis made by five core pathologists was available, which was used as reference. The following criteria were used: (1) percentage of 'indefinite for dysplasia' diagnoses, (2) percentage agreement with consensus diagnosis and (3) proportion of cases with a consensus diagnosis of dysplasia underdiagnosed as non-dysplastic. Benchmarks were based on scores of the core pathologists. RESULTS: After phase I, 1/7 pathologists met the benchmark score for all quality criteria, yet three pathologists only marginally failed the agreement with consensus diagnosis (score 68.3%, benchmark 69%). After a group discussion and phase II, 5/6 remaining aspirant panel members qualified with all scores within the benchmark range. CONCLUSIONS: The Dutch BO review panel now consists of 14 pathologists, who-after structured assessments and group discussions-can be considered homogeneous in their review of biopsies with LGD.

Published
2021

25. Performance of gastrointestinal pathologists within a national digital review panel for Barrett's oesophagus in the Netherlands: Results of 80 prospective biopsy reviews

Author

Klaver, E, Wel, M, Duits, L, Pouw, R, Seldenrijk, K, Offerhaus, J, Visser, M, Ten Kate, F, Biermann, Katharina, Brosens, L, Doukas, Michail, Huysentruyt, C, Karrenbeld, A, Kats-Ugurlu, G, van der Laan, J, van Lijnschoten, I, Moll, F, Ooms, A, Tijssen, J, Meijer, S, Bergman, J, Klaver, E, Wel, M, Duits, L, Pouw, R, Seldenrijk, K, Offerhaus, J, Visser, M, Ten Kate, F, Biermann, Katharina, Brosens, L, Doukas, Michail, Huysentruyt, C, Karrenbeld, A, Kats-Ugurlu, G, van der Laan, J, van Lijnschoten, I, Moll, F, Ooms, A, Tijssen, J, Meijer, S, and Bergman, J

Abstract

Aims The histopathological diagnosis of low-grade dysplasia (LGD) in Barrett's oesophagus (BO) is associated with poor interobserver agreement and guidelines dictate expert review. To facilitate nationwide expert review in the Netherlands, a web-based digital review panel has been set up, which currently consists of eight 'core' pathologists. The aim of this study was to evaluate if other pathologists from the Dutch BO expert centres qualify for the expert panel by assessing their performance in 80 consecutive LGD reviews submitted to the panel. Methods Pathologists independently assessed digital slides in two phases. Both phases consisted of 40 cases, with a group discussion after phase I. For all cases, a previous consensus diagnosis made by five core pathologists was available, which was used as reference. The following criteria were used: (1) percentage of 'indefinite for dysplasia' diagnoses, (2) percentage agreement with consensus diagnosis and (3) proportion of cases with a consensus diagnosis of dysplasia underdiagnosed as non-dysplastic. Benchmarks were based on scores of the core pathologists. Results After phase I, 1/7 pathologists met the benchmark score for all quality criteria, yet three pathologists only marginally failed the agreement with consensus diagnosis (score 68.3%, benchmark 69%). After a group discussion and phase II, 5/6 remaining aspirant panel members qualified with all scores within the benchmark range. Conclusions The Dutch BO review panel now consists of 14 pathologists, who - after structured assessments and group discussions - can be considered homogeneous in their review of biopsies with LGD.

Published
2021

26. Significant variation in histopathological assessment of endoscopic resections for Barrett's neoplasia suggests need for consensus reporting: propositions for improvement

Author

Pathologie Opleiding, Cancer, AIOS Anesthesiologie, Pathologie Pathologen staf, Pathologie Groep Derksen, Trialbureau Beeld, Zorgeenheid Vaatchirurgie Medisch, MS CGO, van der Wel, M. J., Klaver, E., Pouw, R. E., Brosens, L. A.A., Biermann, K., Doukas, M., Huysentruyt, C., Karrenbeld, A., Ten Kate, F. J.W., Kats-Ugurlu, G., van der Laan, J., van Lijnschoten, I., Moll, F. C.P., Offerhaus, G. J.A., Ooms, A. H.A.G., Seldenrijk, C. A., Visser, M., Tijssen, J. G., Meijer, S. L., Bergman, J. J.G.H.M., Pathologie Opleiding, Cancer, AIOS Anesthesiologie, Pathologie Pathologen staf, Pathologie Groep Derksen, Trialbureau Beeld, Zorgeenheid Vaatchirurgie Medisch, MS CGO, van der Wel, M. J., Klaver, E., Pouw, R. E., Brosens, L. A.A., Biermann, K., Doukas, M., Huysentruyt, C., Karrenbeld, A., Ten Kate, F. J.W., Kats-Ugurlu, G., van der Laan, J., van Lijnschoten, I., Moll, F. C.P., Offerhaus, G. J.A., Ooms, A. H.A.G., Seldenrijk, C. A., Visser, M., Tijssen, J. G., Meijer, S. L., and Bergman, J. J.G.H.M.

Published
2021

27. Fluorescence Molecular Endoscopy (FME) Using Bevacizumab-800CW to Evaluate Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer: Preliminary Results

Author

Schmidt, I, additional, Zhao, X, additional, Kats-Ugurlu, G, additional, van der Waaij, A.M, additional, Gabriels, RY, additional, van der Laan, JJ, additional, Dijkstra, FA, additional, Haveman, JW, additional, van Etten, B, additional, Robinson, DJ, additional, and Nagengast, WB, additional

Published
2021
Full Text
View/download PDF

28. QUANTIFICATION OF LYMPHOVASCULAR INVASION IS USEFUL TO PREDICT LYMPH NODE METASTASES IN PATIENTS WITH SUBMUCOSAL (T1B) ESOPHAGEAL ADENOCARCINOMA

Author

van de Ven, SEM, additional, Gotink, AW, additional, Ten Kate, FJC, additional, Nieboer, D, additional, Weusten, BLAM, additional, Brosens, LAA, additional, van Hillegersberg, R, additional, Herrero, LA, additional, Seldenrijk, CA, additional, Alkhalaf, A, additional, Moll, FCP, additional, Curvers, W, additional, van Lijnschoten, I, additional, Tang, T, additional, van der Valk, H, additional, Nagengast, WB, additional, Kats-Ugurlu, G, additional, Plukker, JTM, additional, Houben, MHMG, additional, van der Laan, J, additional, Pouw, RE, additional, Bergman, JJGHM, additional, Meijer, SL, additional, van Berge Henegouwen, MI, additional, Wijnhoven, BPL, additional, de Jonge, PJF, additional, Doukas, M, additional, Bruno, MJ, additional, Biermann, K, additional, and Koch, AD, additional

Published
2020
Full Text
View/download PDF

29. NEAR-INFRARED FLUORESCENCE MOLECULAR ENDOSCOPY SHOWS PROMISING RESULTS IN DETECTING DYSPLASTIC ESOPHAGEAL LESIONS USING TOPICALLY ADMINISTERED BEVACIZUMAB-800CW: THE PRELIMINARY RESULTS OF A PHASE 2 STUDY

Author

Gabriëls, RY, additional, Hooghiemstra, WTR, additional, Schmidt, I, additional, van der Laan, JJH, additional, Kats-Ugurlu, G, additional, Robinson, DJ, additional, Ntziachristos, V, additional, Gkorkas, D, additional, and Nagengast, WB, additional

Published
2020
Full Text
View/download PDF

30. INDIVIDUAL RISK CALCULATOR TO PREDICT LYMPH NODE METASTASES IN PATIENTS WITH SUBMUCOSAL (T1B) ESOPHAGEAL ADENOCARCINOMA: MULTICENTER COHORT STUDY

Author

van de Ven, SEM, additional, Gotink, AW, additional, Kate, FJC Ten, additional, Nieboer, D, additional, Weusten, BLAM, additional, Brosens, LAA, additional, van Hillegersberg, R, additional, Herrero, LA, additional, Seldenrijk, CA, additional, Alkhalaf, A, additional, Moll, FCP, additional, Schoon, EJ, additional, van Lijnschoten, I, additional, Tang, T, additional, van der Valk, H, additional, Nagengast, WB, additional, Kats-Ugurlu, G, additional, Plukker, JTM, additional, Houben, MHMG, additional, van der Laan, J, additional, Pouw, RE, additional, Bergman, JJGHM, additional, Meijer, SL, additional, van Berge Henegouwen, MI, additional, Wijnhoven, BPL, additional, de Jonge, PJF, additional, Doukas, M, additional, Bruno, MJ, additional, Biermann, K, additional, and Koch, AD, additional

Published
2020
Full Text
View/download PDF

31. Pulmonary Lymphangitis Carcinomatosis of Clear Cell Renal Cell Carcinoma After Angiogenesis Inhibition

Author

Kats-Ugurlu, G., Herpen, C.M. van, Mulder, S.F., Prokop, M., Waal, R.M. de, Mulders, P.F.A., Krieken, J.H.J.M. van, Oosterwijk, E., and Leenders, W.P.

Subjects
Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], Other Research Radboud Institute for Health Sciences [Radboudumc 0], Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], General Medicine, Nanomedicine Radboud Institute for Molecular Life Sciences [Radboudumc 19], Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Abstract

Item does not contain fulltext

Published
2020

33. PE-19: Clinically Applicable PEG-based Intraluminal Preservation of Human Small Intestines Does Not Reduce Histological Damage Compared to Standard Vascular Flush

Author

Jacques Pirenne, de Jong A, van Praagh J, Klaas Nico Faber, Trentadue G, Haveman J, Clarysse M, Emilio Canovai, Laurens J. Ceulemans, Gerard Dijkstra, Kats-Ugurlu G, and H Leuvenink

Subjects
Transplantation, Pathology, medicine.medical_specialty, business.industry, PEG ratio, Medicine, business
Published
2021
Full Text
View/download PDF

34. Performance of gastrointestinal pathologists within a national digital review panel for Barrett's oesophagus in the Netherlands: Results of 80 prospective biopsy reviews

Author

Klaver, E. (Esther), Van Der Wel, M. (Myrtle), Duits, L. (Lucas), Pouw, R. (Roos), Seldenrijk, K.A. (Kees), Offerhaus, J. (Johan), Visser, M. (Marjan), Ten Kate, F. (Fiebo), Biermann, K. (Katharina), Brosens, L.A. (Lodewijk), Doukas, M. (Michael), Huysentruyt, C.J. (Clément J.), Karrenbeld, A. (A.), Kats-Ugurlu, G. (Gursah), Van Der Laan, J. (Jaap), Lijnschoten, I. (Ineke) van, Moll, F.C.P., Ooms, A.H.A.G. (Ariadne), Tijssen, J.G.P. (Jan), Meijer, S.L. (Sybren), Bergman, J.J.G.H.M. (Jacques), Klaver, E. (Esther), Van Der Wel, M. (Myrtle), Duits, L. (Lucas), Pouw, R. (Roos), Seldenrijk, K.A. (Kees), Offerhaus, J. (Johan), Visser, M. (Marjan), Ten Kate, F. (Fiebo), Biermann, K. (Katharina), Brosens, L.A. (Lodewijk), Doukas, M. (Michael), Huysentruyt, C.J. (Clément J.), Karrenbeld, A. (A.), Kats-Ugurlu, G. (Gursah), Van Der Laan, J. (Jaap), Lijnschoten, I. (Ineke) van, Moll, F.C.P., Ooms, A.H.A.G. (Ariadne), Tijssen, J.G.P. (Jan), Meijer, S.L. (Sybren), and Bergman, J.J.G.H.M. (Jacques)

Abstract

Aims: The histopathological diagnosis of low-grade dysplasia (LGD) in Barrett's oesophagus (BO) is associated with poor interobserver agreement and guidelines dictate expert review. To facilitate nationwide expert review in the Netherlands, a web-based digital review panel has been set up, which currently consists of eight 'core' pathologists. The aim of this study was to evaluate if other pathologists from the Dutch BO expert centres qualify for the expert panel by assessing their performance in 80 consecutive LGD reviews submitted to the panel. Methods: Pathologists independently assessed digital slides in two phases. Both phases consisted of 40 cases, with a group discussion after phase I. For all cases, a previous consensus diagnosis made by five core pathologists was available, which was used as reference. The following criteria were used: (1) percentage of 'indefinite for dysplasia' diagnoses, (2) percentage agreement with consensus diagnosis and (3) proportion of cases with a consensus diagnosis of dysplasia underdiagnosed as non-dysplastic. Benchmarks were based on scores of the core pathologists. Results: After phase I, 1/7 pathologists met the benchmark score

Published
2020
Full Text
View/download PDF

35. C-Met targeted fluorescence molecular endoscopy in Barrett's esophagus patients and identification of outcome parameters for phase-I studies

Author

de Jongh, S.J., Voskuil, F.J., Schmidt, I., Karrenbeld, A, Kats-Ugurlu, G. (Gursah), Meersma, G.J., Westerhof, J., Witjes, MJ, van Dam, GM, Robinson, D.J. (Dominic), Nagengast, W.B., de Jongh, S.J., Voskuil, F.J., Schmidt, I., Karrenbeld, A, Kats-Ugurlu, G. (Gursah), Meersma, G.J., Westerhof, J., Witjes, MJ, van Dam, GM, Robinson, D.J. (Dominic), and Nagengast, W.B.

Abstract

Fluorescence molecular endoscopy (FME) is an emerging technique in the field of gastroenterology that holds potential to improve diagnosis and guide therapy, by serving as a ‘red-flag’ endoscopic imaging technique. Here, we investigated the safety, feasibility and optimal method of administration of EMI-137, targeting c-Met, during FME in Barrett’s Esophagus (BE) and report several outcome parameters for early phase FME studies. Methods: FME was performed in 15 Barrett’s neoplasia patients. EMI-137 was administered to three cohorts of five patients: 0.13 mg/kg intravenously (IV); 0.09 mg/kg IV or topically at a dose of 200 µg/cm BE (n=1) or 100 µg/cm BE (n=4). Fluorescence was visualized in vivo, quantified in vivo using multi-diameter single-fiber reflectance, single-fiber fluorescence (MDSFR/SFF) spectroscopy and correlated to histopathology and immunohistochemistry. EMI-137 localization was assessed using fluorescence microscopy. Results: FME using different IV and topical doses of

Published
2020
Full Text
View/download PDF

37. Significant variation in histopathological assessment of endoscopic resections for Barrett's neoplasia suggests need for consensus reporting: propositions for improvement.

Author

Wel, M J van der, Klaver, E, Pouw, R E, Brosens, L A A, Biermann, K, Doukas, M, Huysentruyt, C, Karrenbeld, A, Kate, F J W ten, Kats-Ugurlu, G, Laan, J van der, Lijnschoten, I van, Moll, F C P, Offerhaus, G J A, Ooms, A H A G, Seldenrijk, C A, Visser, M, Tijssen, J G, Meijer, S L, and Bergman, J J G H M

Subjects
ENDOSCOPIC surgery, BARRETT'S esophagus, LYMPHATIC metastasis, HISTOPATHOLOGY, TUMORS, ENDOTHELIUM diseases
Abstract

Endoscopic resection (ER) is an important diagnostic step in management of patients with early Barrett's esophagus (BE) neoplasia. Based on ER specimens, an accurate histological diagnosis can be made, which guides further treatment. Based on depth of tumor invasion, differentiation grade, lymphovascular invasion, and margin status, the risk of lymph node metastases and local recurrence is judged to be low enough to justify endoscopic management, or high enough to warrant invasive surgical esophagectomy. Adequate assessment of these histological risk factors is therefore of the utmost importance. Aim of this study was to assess pathologist concordance on these histological features on ER specimens and evaluate causes of discrepancy. Of 62 challenging ER cases, one representative H&E slide and matching desmin and endothelial marker were digitalized and independently assessed by 13 dedicated GI pathologists from 8 Dutch BE expert centers, using an online assessment module. For each histological feature, concordance and discordance were calculated. Clinically relevant discordances were observed for all criteria. Grouping depth of invasion categories according to expanded endoscopic treatment criteria (T1a and T1sm1 vs. T1sm2/3), ≥1 pathologist was discrepant in 21% of cases, increasing to 45% when grouping diagnoses according to the traditional T1a versus T1b classification. For differentiation grade, lymphovascular invasion, and margin status, discordances were substantial with 27%, 42%, and 32% of cases having ≥1 discrepant pathologist, respectively. In conclusion, histological assessment of ER specimens of early BE cancer by dedicated GI pathologists shows significant discordances for all relevant histological features. We present propositions to improve definitions of diagnostic criteria. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

39. Roux loop revision for treatment of focal protein losing enteropathy in the Roux-Y loop after liver transplantation

Author

Holvast, Bert, Bodewes, F.A.J.A., De Kleine, R.H.J., Porte, R.J., Brouwers, A.H., Kats-Ugurlu, G., Van Der Doef, H.P.J., Groningen Institute for Organ Transplantation (GIOT), Guided Treatment in Optimal Selected Cancer Patients (GUTS), and ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)

Subjects
inferior cava vein, conference abstract, endogenous compound, diagnosis, injury, serum albumin, capsule endoscopy, protein losing gastroenteropathy, lymphatic system, technetium 99m, heart, venous congestion, surgery, ascites, metronidazole, male, colonoscopy, controlled study, human, liver vein, catheterization, mucosa, protein expression, albumin, liver biopsy, child, single photon emission computed tomography-computed tomography, posttransplant lymphoproliferative disease, choledochojejunostomy, liver transplantation, central venous pressure, lymphangiectasis, alpha 1 antitrypsin, portal hypertension, torsion, bacterial overgrowth, tracer, infant, obstruction, human tissue, vein blood flow, generalized edema, ornithine transcarbamylase deficiency, injection, gene expression, histopathology, positron emission tomography-computed tomography, hepatojejunostomy, hyperemia
Abstract

Objectives and Study: Protein losing enteropathy (PLE) is a rare complication following paediatric liver transplantation (LTx), mostly related to venous outflow obstruction of the liver. Here, we discuss diagnosing a thus far unknown cause of PLE following paediatric LTx and its surgical treatment. Method: Case-study Results: A boy received an LTx (segments 2 and 3, postmortal heart-beating donor, Roux-en-Y hepaticojejunostomy) at the age of 7 months because of ornithine transcarbamylase deficiency. At the age of 18 months, he developed generalized edema and ascites. PLE was diagnosed, as faecal alpha-1 antitrypsin levels were markedly increased. Clinically, he required suppletion of albumin intravenously every two weeks, for which a venous access port was implanted. Routine diagnostic work-up for PLE was negative. No infectious cause of PLE was found. Endoscopy (gastroduodeno-/ colonoscopy, capsule endoscopy) showed no mucosal injuries and no signs of lymphangiectasia. PET/CT scan showed no signs of post-transplant lymphoproliferative disorder. Vascular origin, most notably venous outflow obstruction, is a known cause of PLE following LTx. Therefore catheterisation was performed, which showed no signs of venous outflow obstruction (normal central venous pressure of 9 mm Hg in the inferior vena cava and normal pressure in the hepatic vein of 9 mmHg), and only a slightly increased wedge pressure in the hepatic vein (19 mmHg). A liver biopsy taken during the same procedure showed no relevant pathology. To find the localization of protein loss, an albumin scan (technetium-99m labeled albumin) was performed, which confirmed intestinal albumin loss. Of note, early recordings (dynamic 0-30 min and early static SPECT-CT recordings at 30, 60, 90 minutes after tracer injection instead of after 120 minutes) were done, to detect where albumin entered the intestine. The affected area on the albumin scan was where the Roux loop was expected. With regard to the albumin loss in the Roux loop, local bacterial overgrowth or local lymphangiectasia, possibly due to (venous) congestion, were considered. Treatment with Metronidazole did not improve albumin loss, rendering local bacterial overgrowth an unlikely cause of the PLE. Therefore a surgical revision of the Roux loop was performed. During the procedure, no torsion of the Roux loop was observed. The explanted loop macroscopically showed a small abnormal area with a thin hyperaemic mucosa (Figure 1A). Histological analysis showed focal lymphangiectasia (Figure 1B), which was considered the site of protein loss. Following surgical revision, PLE disappeared and serum albumin levels remained stable, up to now (6 months post-revision, Figure 1C). We suspect that the local PLE in the Roux loop arose from local congestion of lymphatic outflow. Conclusion: Here, we report diagnosing a thus far unknown cause of PLE following LTx in a child. The Roux loop was found to be the site of albumin loss using early SPECT-CT recordings during an albumin scan. Notably, this was in the absence of relevant portal hypertension. Surgical revision of the Roux loop has stopped the PLE up to now, 6 months post-revision (Figure presented).

Published
2018

40. Adherence to pre‐set benchmark quality criteria to qualify as expert assessor of dysplasia in Barrett's esophagus biopsies – towards digital review of Barrett's esophagus

Author

Wel, MJ, primary, Klaver, E, additional, Duits, LC, additional, Pouw, RE, additional, Seldenrijk, CA, additional, Offerhaus, GJA, additional, Visser, M, additional, Kate, FJW, additional, Biermann, K, additional, Brosens, LAA, additional, Doukas, M, additional, Huysentruyt, C, additional, Karrenbeld, A, additional, Kats-Ugurlu, G, additional, Laan, JS, additional, Lijnschoten, G, additional, Moll, FCP, additional, Ooms, AHAG, additional, Tijssen, JG, additional, Bergman, JJGHM, additional, and Meijer, SL, additional

Published
2019
Full Text
View/download PDF

41. Adherence to pre-set benchmark quality criteria to qualify as expert assessor of dysplasia in Barrett's esophagus biopsies - towards digital review of Barrett's esophagus

Author

van der Wel, M J, Klaver, E, Duits, L C, Pouw, R E, Seldenrijk, C A, Offerhaus, Gja, Visser, M, Ten Kate, Fjw, Biermann, K, Brosens, Laa, Doukas, M, Huysentruyt, C, Karrenbeld, A, Kats-Ugurlu, G, van der Laan, J S, van Lijnschoten, G, Moll, Fcp, Ooms, Ahag, Tijssen, J G, Bergman, Jjghm, Meijer, S L, van der Wel, M J, Klaver, E, Duits, L C, Pouw, R E, Seldenrijk, C A, Offerhaus, Gja, Visser, M, Ten Kate, Fjw, Biermann, K, Brosens, Laa, Doukas, M, Huysentruyt, C, Karrenbeld, A, Kats-Ugurlu, G, van der Laan, J S, van Lijnschoten, G, Moll, Fcp, Ooms, Ahag, Tijssen, J G, Bergman, Jjghm, and Meijer, S L

Published
2019

42. Adherence to pre-set benchmark quality criteria to qualify as expert assessor of dysplasia in Barrett’s esophagus biopsies – towards digital review of Barrett’s esophagus

Author

van der Wel, M.J. (M. J.), Klaver, E. (E.), Duits, L.C. (L. C.), Pouw, R.E. (R. E.), Seldenrijk, K.A. (Kees), Offerhaus, G.J.A. (Johan), Visser, M. (Marjan), ten Kate, F.J.W. (F. J.W.), Biermann, K. (Katharina), Brosens, L.A. (Lodewijk), Doukas, M. (M.), Huysentruyt, C.J. (Clément J.), Karrenbeld, A. (A.), Kats-Ugurlu, G. (Gursah), van der Laan, J.S. (J. S.), Lijnschoten, G. van, Moll, F.C.P., Ooms, A.H.A.G. (Ariadne), Tijssen, J.G.P. (Jan), Bergman, J.J.G.H.M. (Jacques), Meijer, S.L. (Sybren), van der Wel, M.J. (M. J.), Klaver, E. (E.), Duits, L.C. (L. C.), Pouw, R.E. (R. E.), Seldenrijk, K.A. (Kees), Offerhaus, G.J.A. (Johan), Visser, M. (Marjan), ten Kate, F.J.W. (F. J.W.), Biermann, K. (Katharina), Brosens, L.A. (Lodewijk), Doukas, M. (M.), Huysentruyt, C.J. (Clément J.), Karrenbeld, A. (A.), Kats-Ugurlu, G. (Gursah), van der Laan, J.S. (J. S.), Lijnschoten, G. van, Moll, F.C.P., Ooms, A.H.A.G. (Ariadne), Tijssen, J.G.P. (Jan), Bergman, J.J.G.H.M. (Jacques), and Meijer, S.L. (Sybren)

Abstract

Background: Dysplasia assessment of Barrett’s esophagus biopsies is associated with low observer agreement; guidelines advise expert review. We have developed a web-based review panel for dysplastic Barrett’s esophagus biopsies. Objective: The purpose of this study was to test if 10 gastrointestinal pathologists working at Dutch Barrett’s esophagus expert centres met pre-set benchmark scores for quality criteria. Methods: Ten gastrointestinal pathologists twice assessed 60 digitalized Barrett’s esophagus cases, enriched for dysplasia; then r

Published
2019
Full Text
View/download PDF

43. Adherence to pre-set benchmark quality criteria to qualify as expert assessor of dysplasia in Barrett's esophagus biopsies - towards digital review of Barrett's esophagus

Author

MS CGO, Pathologie Pathologen staf, Cancer, van der Wel, M J, Klaver, E, Duits, L C, Pouw, R E, Seldenrijk, C A, Offerhaus, Gja, Visser, M, Ten Kate, Fjw, Biermann, K, Brosens, Laa, Doukas, M, Huysentruyt, C, Karrenbeld, A, Kats-Ugurlu, G, van der Laan, J S, van Lijnschoten, G, Moll, Fcp, Ooms, Ahag, Tijssen, J G, Bergman, Jjghm, Meijer, S L, MS CGO, Pathologie Pathologen staf, Cancer, van der Wel, M J, Klaver, E, Duits, L C, Pouw, R E, Seldenrijk, C A, Offerhaus, Gja, Visser, M, Ten Kate, Fjw, Biermann, K, Brosens, Laa, Doukas, M, Huysentruyt, C, Karrenbeld, A, Kats-Ugurlu, G, van der Laan, J S, van Lijnschoten, G, Moll, Fcp, Ooms, Ahag, Tijssen, J G, Bergman, Jjghm, and Meijer, S L

Published
2019

44. Adherence to pre-set benchmark quality criteria to qualify as expert assessor of dysplasia in Barrett's esophagus biopsies - towards digital review of Barrett's esophagus

Author

van der Wel, MJ (Maria Jacoba), Klaver, E, Duits, LC, Pouw, RE, Seldenrijk, CA, Offerhaus, GJA, Visser, M, ten Kate, FJW, Biermann, Katharina, Brosens, LAA, Doukas, Michail, Huysentruye, C, Karrenbeld, A, Kats-Ugurlu, G, van der Laan, JS, van Lijnschoten, G, Moll, FCP, Ooms, A, Tijssen, JG, Bergman, J, Meijer, SL, van der Wel, MJ (Maria Jacoba), Klaver, E, Duits, LC, Pouw, RE, Seldenrijk, CA, Offerhaus, GJA, Visser, M, ten Kate, FJW, Biermann, Katharina, Brosens, LAA, Doukas, Michail, Huysentruye, C, Karrenbeld, A, Kats-Ugurlu, G, van der Laan, JS, van Lijnschoten, G, Moll, FCP, Ooms, A, Tijssen, JG, Bergman, J, and Meijer, SL

Published
2019

45. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): A multicenter observational study

Author

Borggreve, A. S., Mook, S., Verheij, M., Mul, V. E.M., Bergman, J. J., Bartels-Rutten, A., Ter Beek, L. C., Beets-Tan, R. G.H., Bennink, R. J., Van Berge Henegouwen, M. I., Brosens, L. A.A., Defize, I. L., Van Dieren, J. M., Dijkstra, H., Van Hillegersberg, R., Hulshof, M. C., Van Laarhoven, H. W.M., Lam, M. G.E.H., Van Lier, A. L.H.M.W., Muijs, C. T., Nagengast, W. B., Nederveen, A. J., Noordzij, W., Plukker, J. T.M., Van Rossum, P. S.N., Ruurda, J. P., Van Sandick, J. W., Weusten, B. L.A.M., Voncken, F. E.M., Yakar, D., Meijer, G. J., Aleman, B. M.P., Borra, R. J.H., Van Etten, B., Gisbertz, S. S., Goense, L., Haj Mohammad, N., Hartemink, K. J., Kappert, P., Kats-Ugurlu, G., Kodach, L. L., Korteweg, T., Krishnadath, K. K., Langendijk, J. A., De Leng, W. W.J., Meijer, S. L., Potze, J. H., Stoker, J., Vegt, E., Verkooijen, H. M., Vollenbrock, S. E., Wessels, F., Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Gastroenterology and Hepatology, AGEM - Re-generation and cancer of the digestive system, Nuclear Medicine, Radiology and Nuclear Medicine, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Surgery, CCA - Imaging and biomarkers, Radiotherapy, Oncology, ACS - Diabetes & metabolism, AMS - Restoration & Development, ANS - Brain Imaging, Pathology, and AGEM - Digestive immunity

Subjects
Cancer Research, Esophageal Neoplasms, PREDICTION, SURGERY, medicine.medical_treatment, Esophageal cancer, FREE DNA, Study Protocol, 0302 clinical medicine, Positron Emission Tomography Computed Tomography, Pathologic complete response, PATHOLOGICAL COMPLETE RESPONSE, FDG-PET, medicine.diagnostic_test, Image-guided, Chemoradiotherapy, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Primary tumor, Neoadjuvant Therapy, Neoadjuvant chemoradiotherapy, medicine.anatomical_structure, Fine-needle aspiration, Treatment Outcome, Oncology, Positron emission tomography, Esophagectomy, 030220 oncology & carcinogenesis, GASTROESOPHAGEAL CANCER, Adenocarcinoma, 030211 gastroenterology & hepatology, Radiology, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], MRI, medicine.medical_specialty, DCE-MRI, PET-CT, lcsh:RC254-282, 03 medical and health sciences, POSITRON-EMISSION-TOMOGRAPHY, DW-MRI, Preoperative Care, medicine, Genetics, Humans, Esophagus, JUNCTIONAL CANCER, business.industry, PERIOPERATIVE CHEMOTHERAPY, ctDNA, medicine.disease, CIRCULATING TUMOR-CELLS, business, Follow-Up Studies
Abstract

Contains fulltext : 200332.pdf (Publisher’s version ) (Open Access) BACKGROUND: Nearly one third of patients undergoing neoadjuvant chemoradiotherapy (nCRT) for locally advanced esophageal cancer have a pathologic complete response (pCR) of the primary tumor upon histopathological evaluation of the resection specimen. The primary aim of this study is to develop a model that predicts the probability of pCR to nCRT in esophageal cancer, based on diffusion-weighted magnetic resonance imaging (DW-MRI), dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and (18)F-fluorodeoxyglucose positron emission tomography with computed tomography ((18)F-FDG PET-CT). Accurate response prediction could lead to a patient-tailored approach with omission of surgery in the future in case of predicted pCR or additional neoadjuvant treatment in case of non-pCR. METHODS: The PRIDE study is a prospective, single arm, observational multicenter study designed to develop a multimodal prediction model for histopathological response to nCRT for esophageal cancer. A total of 200 patients with locally advanced esophageal cancer - of which at least 130 patients with adenocarcinoma and at least 61 patients with squamous cell carcinoma - scheduled to receive nCRT followed by esophagectomy will be included. The primary modalities to be incorporated in the prediction model are quantitative parameters derived from MRI and (18)F-FDG PET-CT scans, which will be acquired at fixed intervals before, during and after nCRT. Secondary modalities include blood samples for analysis of the presence of circulating tumor DNA (ctDNA) at 3 time-points (before, during and after nCRT), and an endoscopy with (random) bite-on-bite biopsies of the primary tumor site and other suspected lesions in the esophagus as well as an endoscopic ultrasonography (EUS) with fine needle aspiration of suspected lymph nodes after finishing nCRT. The main study endpoint is the performance of the model for pCR prediction. Secondary endpoints include progression-free and overall survival. DISCUSSION: If the multimodal PRIDE concept provides high predictive performance for pCR, the results of this study will play an important role in accurate identification of esophageal cancer patients with a pCR to nCRT. These patients might benefit from a patient-tailored approach with omission of surgery in the future. Vice versa, patients with non-pCR might benefit from additional neoadjuvant treatment, or ineffective therapy could be stopped. TRIAL REGISTRATION: The article reports on a health care intervention on human participants and was prospectively registered on March 22, 2018 under ClinicalTrials.gov Identifier: NCT03474341 .

Published
2018

46. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): A multicenter observational study

Author

Onderzoek Radiotherapie, MS Radiotherapie, Cancer, Pathologie Pathologen staf, Fysica Radiotherapie Research, Divisie Beeld & Oncologie, Researchgr. Nucleaire Geneeskunde, Arts-assistenten Radiotherapie, MS CGO, MS MDL 1, Klinische Fysica RT, Verpleegafdeling Hematologie, Unit D (laboranten rath), Trialbureau Beeld, Epi Kanker Team A, Circulatory Health, JC onderzoeksprogramma Kanker, MS Radiologie, Borggreve, A. S., Mook, S., Verheij, M., Mul, V. E.M., Bergman, J. J., Bartels-Rutten, A., Ter Beek, L. C., Beets-Tan, R. G.H., Bennink, R. J., Van Berge Henegouwen, M. I., Brosens, L. A.A., Defize, I. L., Van Dieren, J. M., Dijkstra, H., Van Hillegersberg, R., Hulshof, M. C., Van Laarhoven, H. W.M., Lam, M. G.E.H., Van Lier, A. L.H.M.W., Muijs, C. T., Nagengast, W. B., Nederveen, A. J., Noordzij, W., Plukker, J. T.M., Van Rossum, P. S.N., Ruurda, J. P., Van Sandick, J. W., Weusten, B. L.A.M., Voncken, F. E.M., Yakar, D., Meijer, G. J., Aleman, B. M.P., Borra, R. J.H., Van Etten, B., Gisbertz, S. S., Goense, L., Haj Mohammad, N., Hartemink, K. J., Kappert, P., Kats-Ugurlu, G., Kodach, L. L., Korteweg, T., Krishnadath, K. K., Langendijk, J. A., De Leng, W. W.J., Meijer, S. L., Potze, J. H., Stoker, J., Vegt, E., Verkooijen, H. M., Vollenbrock, S. E., Wessels, F., Onderzoek Radiotherapie, MS Radiotherapie, Cancer, Pathologie Pathologen staf, Fysica Radiotherapie Research, Divisie Beeld & Oncologie, Researchgr. Nucleaire Geneeskunde, Arts-assistenten Radiotherapie, MS CGO, MS MDL 1, Klinische Fysica RT, Verpleegafdeling Hematologie, Unit D (laboranten rath), Trialbureau Beeld, Epi Kanker Team A, Circulatory Health, JC onderzoeksprogramma Kanker, MS Radiologie, Borggreve, A. S., Mook, S., Verheij, M., Mul, V. E.M., Bergman, J. J., Bartels-Rutten, A., Ter Beek, L. C., Beets-Tan, R. G.H., Bennink, R. J., Van Berge Henegouwen, M. I., Brosens, L. A.A., Defize, I. L., Van Dieren, J. M., Dijkstra, H., Van Hillegersberg, R., Hulshof, M. C., Van Laarhoven, H. W.M., Lam, M. G.E.H., Van Lier, A. L.H.M.W., Muijs, C. T., Nagengast, W. B., Nederveen, A. J., Noordzij, W., Plukker, J. T.M., Van Rossum, P. S.N., Ruurda, J. P., Van Sandick, J. W., Weusten, B. L.A.M., Voncken, F. E.M., Yakar, D., Meijer, G. J., Aleman, B. M.P., Borra, R. J.H., Van Etten, B., Gisbertz, S. S., Goense, L., Haj Mohammad, N., Hartemink, K. J., Kappert, P., Kats-Ugurlu, G., Kodach, L. L., Korteweg, T., Krishnadath, K. K., Langendijk, J. A., De Leng, W. W.J., Meijer, S. L., Potze, J. H., Stoker, J., Vegt, E., Verkooijen, H. M., Vollenbrock, S. E., and Wessels, F.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results